ea0014p476 | (1) | ECE2007
Sánchez-Juan Carlos
, Gamón Elena Roche
, Fabra Xelo García
, Miquel Victor Alegre de
, Galera Raquel Albalat
, García Juan-Carlos Ferrer
Background and aims: Bexarotene is the first retinoid receptor X (RXR)-selective agonist approved for cutaneous T-cell lymphoma in patients resistant to at least one previus systemic treatment. However, it produces often two endocrine-metabolic alterations: central hypothyroidism and dyslipidemia. We assessed, in a group of patients with Mycosis Fungoide or Sezary syndrome treated with bexarotene, the endocrine-metabolic side effects.Patients and methods...